Speaker Profile

Ph.D., CEO, Foresight Diagnostics

Dr. Chabon is a co-founder of Foresight Diagnostics where he is focused on commercializing a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that enables detection of ctDNA at levels as low as one part-per-million. He is a molecular biologist and bioinformatic scientist by training with extensive NGS assay development experience. He has authored more than 20 peer-reviewed publications and has 3,000+ citations to date (including papers published in Nature and Nature Biotechnology describing Foresight’s liquid biopsy platform). Prior to founding Foresight, Dr. Chabon’s research focused on using cancer genomics to inform better personalized treatment strategies for patients. He completed his Ph.D and postdoctoral training at Stanford University under the co-mentorship of Dr. Max Diehn and Dr. Ash Alizadeh with whom he co-founded Foresight Diagnostics in 2020.

Clinical Dx Showcase:
Foresight Diagnostics

Foresight Diagnostics is developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD). The improved sensitivity of the Foresight MRD assay can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches.

Foresight’s Ultra-Sensitive Liquid Biopsy Improves MRD
Foresight’s ultra-sensitive liquid biopsy platform improves MRD detection rates in patients with B-cell lymphomas and solid tumors by tracking a unique class of somatic mutation, termed ‘phased variants’, that enables detection of ctDNA at levels as low as one part-per-million.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative